Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas

Anubhav G. Amin, Julie Ng, Wesley Hsu, Gustavo Pradilla, Shaan Raza, Alfredo Quinones-Hinojosa, Michael Lim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Thromboembolic events and anticoagulation-associated bleeding events represent frequent complications following cardiac mechanical valve replacement. Management guidelines regarding the timing for resuming anticoagulation therapy following a surgically treated subdural hematoma (SDH) in patients with mechanical valves remains to be determined. Objective: To determine optimal anticoagulation management in patients with mechanical heart valves following treatment of SDH. Methods: Outcomes were retrospectively reviewed for 12 patients on anticoagulation therapy for thromboembolic prophylaxis for mechanical cardiac valves who underwent surgical intervention for a SDH at the Johns Hopkins Hospital between 1995 and 2010. Results: The mean age at admission was 71 years. All patients had St. Jude's mechanical heart valves and were receiving anticoagulation therapy. All patients had their anticoagulation reversed with vitamin K and fresh frozen plasma and underwent surgical evacuation. Anticoagulation was withheld for a mean of 14 days upon admission and a mean of 9 days postoperatively. The average length of stay was 19 days. No deaths or thromboembolic events occurred during the hospitalization. Average follow-up time was 50 months, during which two patients had a recurrent SDH. No other associated morbidities occurred during follow-up. Conclusion: Interruptions in anticoagulation therapy for up to 3 weeks pose minimal thromboembolic risk in patients with mechanical heart valves. Close follow-up after discharge is highly recommended, as recurrent hemorrhages can occur several weeks after the resumption of anticoagulation.

Original languageEnglish (US)
Pages (from-to)90-94
Number of pages5
JournalNeurocritical Care
Volume19
Issue number1
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Subdural Hematoma
Heart Valves
Therapeutics
Hemorrhage
Vitamin K
Length of Stay
Hospitalization
Guidelines
Morbidity

Keywords

  • Anticoagulation
  • Hemorrhage
  • Mechanical heart valve
  • Subdural hematoma
  • Thromboembolism

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas. / Amin, Anubhav G.; Ng, Julie; Hsu, Wesley; Pradilla, Gustavo; Raza, Shaan; Quinones-Hinojosa, Alfredo; Lim, Michael.

In: Neurocritical Care, Vol. 19, No. 1, 08.2013, p. 90-94.

Research output: Contribution to journalArticle

Amin, Anubhav G. ; Ng, Julie ; Hsu, Wesley ; Pradilla, Gustavo ; Raza, Shaan ; Quinones-Hinojosa, Alfredo ; Lim, Michael. / Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas. In: Neurocritical Care. 2013 ; Vol. 19, No. 1. pp. 90-94.
@article{101df31d392b489685a84777c4f48e6b,
title = "Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas",
abstract = "Background: Thromboembolic events and anticoagulation-associated bleeding events represent frequent complications following cardiac mechanical valve replacement. Management guidelines regarding the timing for resuming anticoagulation therapy following a surgically treated subdural hematoma (SDH) in patients with mechanical valves remains to be determined. Objective: To determine optimal anticoagulation management in patients with mechanical heart valves following treatment of SDH. Methods: Outcomes were retrospectively reviewed for 12 patients on anticoagulation therapy for thromboembolic prophylaxis for mechanical cardiac valves who underwent surgical intervention for a SDH at the Johns Hopkins Hospital between 1995 and 2010. Results: The mean age at admission was 71 years. All patients had St. Jude's mechanical heart valves and were receiving anticoagulation therapy. All patients had their anticoagulation reversed with vitamin K and fresh frozen plasma and underwent surgical evacuation. Anticoagulation was withheld for a mean of 14 days upon admission and a mean of 9 days postoperatively. The average length of stay was 19 days. No deaths or thromboembolic events occurred during the hospitalization. Average follow-up time was 50 months, during which two patients had a recurrent SDH. No other associated morbidities occurred during follow-up. Conclusion: Interruptions in anticoagulation therapy for up to 3 weeks pose minimal thromboembolic risk in patients with mechanical heart valves. Close follow-up after discharge is highly recommended, as recurrent hemorrhages can occur several weeks after the resumption of anticoagulation.",
keywords = "Anticoagulation, Hemorrhage, Mechanical heart valve, Subdural hematoma, Thromboembolism",
author = "Amin, {Anubhav G.} and Julie Ng and Wesley Hsu and Gustavo Pradilla and Shaan Raza and Alfredo Quinones-Hinojosa and Michael Lim",
year = "2013",
month = "8",
doi = "10.1007/s12028-012-9704-2",
language = "English (US)",
volume = "19",
pages = "90--94",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas

AU - Amin, Anubhav G.

AU - Ng, Julie

AU - Hsu, Wesley

AU - Pradilla, Gustavo

AU - Raza, Shaan

AU - Quinones-Hinojosa, Alfredo

AU - Lim, Michael

PY - 2013/8

Y1 - 2013/8

N2 - Background: Thromboembolic events and anticoagulation-associated bleeding events represent frequent complications following cardiac mechanical valve replacement. Management guidelines regarding the timing for resuming anticoagulation therapy following a surgically treated subdural hematoma (SDH) in patients with mechanical valves remains to be determined. Objective: To determine optimal anticoagulation management in patients with mechanical heart valves following treatment of SDH. Methods: Outcomes were retrospectively reviewed for 12 patients on anticoagulation therapy for thromboembolic prophylaxis for mechanical cardiac valves who underwent surgical intervention for a SDH at the Johns Hopkins Hospital between 1995 and 2010. Results: The mean age at admission was 71 years. All patients had St. Jude's mechanical heart valves and were receiving anticoagulation therapy. All patients had their anticoagulation reversed with vitamin K and fresh frozen plasma and underwent surgical evacuation. Anticoagulation was withheld for a mean of 14 days upon admission and a mean of 9 days postoperatively. The average length of stay was 19 days. No deaths or thromboembolic events occurred during the hospitalization. Average follow-up time was 50 months, during which two patients had a recurrent SDH. No other associated morbidities occurred during follow-up. Conclusion: Interruptions in anticoagulation therapy for up to 3 weeks pose minimal thromboembolic risk in patients with mechanical heart valves. Close follow-up after discharge is highly recommended, as recurrent hemorrhages can occur several weeks after the resumption of anticoagulation.

AB - Background: Thromboembolic events and anticoagulation-associated bleeding events represent frequent complications following cardiac mechanical valve replacement. Management guidelines regarding the timing for resuming anticoagulation therapy following a surgically treated subdural hematoma (SDH) in patients with mechanical valves remains to be determined. Objective: To determine optimal anticoagulation management in patients with mechanical heart valves following treatment of SDH. Methods: Outcomes were retrospectively reviewed for 12 patients on anticoagulation therapy for thromboembolic prophylaxis for mechanical cardiac valves who underwent surgical intervention for a SDH at the Johns Hopkins Hospital between 1995 and 2010. Results: The mean age at admission was 71 years. All patients had St. Jude's mechanical heart valves and were receiving anticoagulation therapy. All patients had their anticoagulation reversed with vitamin K and fresh frozen plasma and underwent surgical evacuation. Anticoagulation was withheld for a mean of 14 days upon admission and a mean of 9 days postoperatively. The average length of stay was 19 days. No deaths or thromboembolic events occurred during the hospitalization. Average follow-up time was 50 months, during which two patients had a recurrent SDH. No other associated morbidities occurred during follow-up. Conclusion: Interruptions in anticoagulation therapy for up to 3 weeks pose minimal thromboembolic risk in patients with mechanical heart valves. Close follow-up after discharge is highly recommended, as recurrent hemorrhages can occur several weeks after the resumption of anticoagulation.

KW - Anticoagulation

KW - Hemorrhage

KW - Mechanical heart valve

KW - Subdural hematoma

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84880924227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880924227&partnerID=8YFLogxK

U2 - 10.1007/s12028-012-9704-2

DO - 10.1007/s12028-012-9704-2

M3 - Article

VL - 19

SP - 90

EP - 94

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 1

ER -